{"id":602,"date":"2026-01-12T07:57:48","date_gmt":"2026-01-12T15:57:48","guid":{"rendered":"https:\/\/www.leapfrog.bio\/?p=602"},"modified":"2026-01-12T10:23:19","modified_gmt":"2026-01-12T18:23:19","slug":"new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal","status":"publish","type":"post","link":"https:\/\/www.leapfrog.bio\/fr\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/","title":{"rendered":"De nouvelles donn\u00e9es publi\u00e9es dans une revue du portefeuille Nature mettent en \u00e9vidence la capacit\u00e9 de la plateforme OncoSLX de Leapfrog Bio \u00e0 identifier des opportunit\u00e9s de repositionnement de m\u00e9dicaments en oncologie"},"content":{"rendered":"

\u2014 Une \u00e9tude souligne l'importance de la biologie des facteurs oncog\u00e8nes dans la transposition des r\u00e9sultats du laboratoire aux patients \u2014<\/span>
\u2014 Les r\u00e9sultats valident la plateforme exclusive OncoSLX\u2122, une approche pharmacog\u00e9n\u00e9tique qui permet de capter l\u2019ensemble de la biologie des m\u00e9dicaments \u2014<\/span>
\u2014 Poursuite du d\u00e9veloppement de l\u2019actif principal LFB190, un inhibiteur de BET ciblant les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300; lancement pr\u00e9vu d\u2019un essai clinique de phase 1b\/2a dans les tumeurs solides \u00e0 la mi-2026 \u2014<\/span><\/p>\n

South San Francisco (Californie), le 12 janvier 2026 <\/b>(Lire sur GlobeNewswire<\/u><\/a>)<\/span> \u2014<\/b> Leapfrog Bio, une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de nouvelles th\u00e9rapies cibl\u00e9es pour les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF), a annonc\u00e9 aujourd\u2019hui la publication d\u2019une \u00e9tude \u00e9valu\u00e9e par des pairs dans la revue npj Systems Biology and Applications, une publication du portefeuille Nature, intitul\u00e9e \u00ab<\/span>C<\/span>hallenges and opportunities for oncology drug repurposing informed by synthetic lethality<\/u><\/a><\/span>. \u00bb L\u2019article propose un cadre pratique pour le repositionnement de m\u00e9dicaments en oncologie et met en lumi\u00e8re des d\u00e9couvertes cl\u00e9s ayant contribu\u00e9 \u00e0 orienter l\u2019optimisation de la plateforme OncoSLX de Leapfrog Bio.<\/span><\/p>\n

\u00ab Cet article confirme deux r\u00e9alit\u00e9s fondamentales en d\u00e9couverte de m\u00e9dicaments anticanc\u00e9reux cibl\u00e9s : les opportunit\u00e9s de ciblage g\u00e9n\u00e9tique identifi\u00e9es dans des lign\u00e9es cellulaires sont plus susceptibles de se confirmer en clinique lorsqu\u2019elles sont associ\u00e9es \u00e0 une mutation conductrice, et les m\u00e9dicaments se comportent tr\u00e8s diff\u00e9remment des invalidations g\u00e9n\u00e9tiques; il est donc essentiel de les \u00e9valuer en fonction de la biologie causale \u00bb, a d\u00e9clar\u00e9 Tomas Babak, Ph. D., fondateur et directeur scientifique de Leapfrog Bio et coauteur de la publication.\n\n\u00ab Notre plateforme OncoSLX repose sur ces principes et nous permet de r\u00e9aliser des milliers de tests m\u00e9dicament\u2013mutation en parall\u00e8le, couvrant l\u2019ensemble des mutations conductrices du cancer, afin d\u2019identifier rapidement des traitements puissants et cibl\u00e9s pour les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF). \u00bb<\/p>\n

Le Dr Babak a poursuivi : \u00ab En \u00e9valuant des m\u00e9dicaments d\u00e9j\u00e0 jug\u00e9s s\u00fbrs en clinique, nous pouvons reprendre leur d\u00e9veloppement directement en phase 2 chez des patients s\u00e9lectionn\u00e9s sur la base de crit\u00e8res g\u00e9n\u00e9tiques, o\u00f9 la probabilit\u00e9 d\u2019efficacit\u00e9 est plus \u00e9lev\u00e9e. Nous nous attendons \u00e0 ce que cette approche acc\u00e9l\u00e8re consid\u00e9rablement le d\u00e9veloppement tout en en r\u00e9duisant les risques \u00e0 mesure que nous progressons. \u00bb<\/p>\n

\u00ab Leapfrog Bio a \u00e9t\u00e9 fond\u00e9e afin d\u2019apporter les b\u00e9n\u00e9fices transformateurs des th\u00e9rapies de pr\u00e9cision aux nombreux patients atteints de cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF), pour lesquels les options cibl\u00e9es demeurent limit\u00e9es \u00bb, a d\u00e9clar\u00e9 Greg Vontz, chef de la direction de Leapfrog Bio.\n\n\u00ab Parmi nos d\u00e9couvertes les plus prometteuses \u00e0 ce jour figure la vuln\u00e9rabilit\u00e9 des cancers li\u00e9s \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300 aux inhibiteurs de BET, comme notre principal candidat, LFB190. Gr\u00e2ce aux enseignements tir\u00e9s de notre plateforme OncoSLX, nous sommes bien positionn\u00e9s pour faire progresser LFB190 directement vers les phases interm\u00e9diaires de d\u00e9veloppement clinique. Nous pr\u00e9voyons lancer notre essai clinique de phase 1b\/2a \u00e0 la mi-2026. \u00bb<\/p>\n

LFB190 est un inhibiteur de BET \u00e0 petite mol\u00e9cule administr\u00e9 par voie orale, potentiellement le meilleur de sa cat\u00e9gorie, en cours de d\u00e9veloppement pour les plus de 60 000 patients am\u00e9ricains diagnostiqu\u00e9s chaque ann\u00e9e avec des tumeurs solides associ\u00e9es \u00e0 des mutations du g\u00e8ne EP300, notamment les cancers du poumon non \u00e0 petites cellules, de la vessie, du c\u00f4lon, du pancr\u00e9as, de la t\u00eate et du cou, ainsi que des voies biliaires.\n\nBien que les inhibiteurs de BET aient \u00e9t\u00e9 largement \u00e9tudi\u00e9s dans diverses indications oncologiques, leur efficacit\u00e9 est demeur\u00e9e limit\u00e9e dans des populations non s\u00e9lectionn\u00e9es sur le plan g\u00e9n\u00e9tique. Des \u00e9tudes pr\u00e9cliniques approfondies ont d\u00e9montr\u00e9 qu\u2019ils peuvent \u00eatre hautement efficaces dans le traitement des cancers li\u00e9s \u00e0 EP300, et les donn\u00e9es issues du d\u00e9veloppement clinique ant\u00e9rieur de LFB190, en tant que th\u00e9rapie non cibl\u00e9e, ont mis en \u00e9vidence un profil d\u2019innocuit\u00e9 et de tol\u00e9rance favorable.<\/p>\n

\u00c0 propos de la plateforme OncoSLX
<\/b>La plateforme OncoSLX est la plateforme pharmacog\u00e9n\u00e9tique exclusive de Leapfrog Bio, qui permet d\u2019\u00e9valuer des compos\u00e9s \u00e0 petites mol\u00e9cules cliniquement caract\u00e9ris\u00e9s \u00e0 l\u2019aide de mod\u00e8les isog\u00e9niques de mutations conductrices du cancer, avec un accent particulier sur la biologie des pertes de fonction.\n\nContrairement aux approches traditionnelles de l\u00e9talit\u00e9 synth\u00e9tique fond\u00e9es sur des invalidations g\u00e9n\u00e9tiques, OncoSLX capte l\u2019ensemble de la biologie des m\u00e9dicaments et int\u00e8gre ensuite des donn\u00e9es issues du monde r\u00e9el afin de prioriser les indications les plus susceptibles d\u2019apporter un b\u00e9n\u00e9fice en survie, tout en r\u00e9duisant les d\u00e9lais de d\u00e9veloppement et les risques de traduction clinique.\n\nCette approche permet d\u2019identifier de nouveaux traitements pour les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction qui ne peuvent \u00eatre d\u00e9couverts par les m\u00e9thodes conventionnelles.<\/p>\n

\u00c0 propos de LFB190 et des cancers associ\u00e9s \u00e0 des mutations du g\u00e8ne EP300
<\/b>LFB190 est un nouvel inhibiteur de BET oral d\u00e9velopp\u00e9 pour le traitement de tumeurs solides associ\u00e9es \u00e0 des mutations avec perte de fonction (LOF) du g\u00e8ne EP300. La plateforme OncoSLX de Leapfrog Bio a mis en \u00e9vidence une nouvelle relation de l\u00e9talit\u00e9 synth\u00e9tique entre les inhibiteurs de BET et les mutations LOF d\u2019EP300, un facteur de d\u00e9veloppement tumoral fr\u00e9quent pour lequel aucune th\u00e9rapie cibl\u00e9e n\u2019est actuellement disponible.\n\nLFB190 a d\u00e9montr\u00e9 une forte efficacit\u00e9 pr\u00e9clinique dans des mod\u00e8les de x\u00e9nogreffes d\u00e9riv\u00e9es de patients (PDX) de cancers associ\u00e9s \u00e0 des mutations d\u2019EP300. EP300 est un g\u00e8ne suppresseur de tumeurs impliqu\u00e9 dans le remodelage de la chromatine et la r\u00e9gulation transcriptionnelle. Lorsqu\u2019il est mut\u00e9, sa perte de fonction contribue \u00e0 la progression tumorale dans de nombreux types de cancer, notamment environ 6 % des cancers du poumon non \u00e0 petites cellules (CPNPC), environ 15 % des cancers de la vessie, ainsi qu\u2019\u00e0 des fr\u00e9quences similaires dans les cancers du c\u00f4lon, du pancr\u00e9as et de la t\u00eate et du cou.\n\nBien que les inhibiteurs de BET aient historiquement montr\u00e9 une efficacit\u00e9 limit\u00e9e dans des populations non s\u00e9lectionn\u00e9es, la plateforme de Leapfrog Bio a mis en \u00e9vidence un effet particuli\u00e8rement prometteur dans les tumeurs associ\u00e9es \u00e0 des mutations d\u2019EP300.<\/p>\n

\u00c0 propos de Leapfrog Bio
<\/b>Leapfrog Bio est une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique qui acc\u00e9l\u00e8re le d\u00e9veloppement de m\u00e9dicaments contre le cancer en identifiant des mol\u00e9cules d\u00e9j\u00e0 en phase clinique pouvant \u00eatre repositionn\u00e9es comme th\u00e9rapies de pr\u00e9cision pour des cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF).\n\nSon principal programme, LFB190, est un inhibiteur de BET oral \u00e0 petite mol\u00e9cule, premier de sa cat\u00e9gorie et pr\u00eat pour la phase 2, destin\u00e9 au traitement de tumeurs solides associ\u00e9es \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300.\n\nLeapfrog Bio s\u2019appuie sur sa plateforme exclusive OncoSLX pour identifier des m\u00e9dicaments \u00e0 petites mol\u00e9cules existants pouvant \u00eatre d\u00e9velopp\u00e9s afin de traiter des cancers li\u00e9s \u00e0 des mutations avec perte de fonction, avec une forte probabilit\u00e9 de succ\u00e8s clinique.\n\nLeapfrog Bio est actuellement financ\u00e9e au stade d\u2019amor\u00e7age par l\u2019investisseur de premier plan Two Bear Capital. Pour en savoir plus, visitez www.leapfrog.bio<\/u><\/a>.<\/p>\n

Relations avec les investisseurs<\/b>:
Amanda Isacoff
Precision AQ
amanda.isacoff@precisionaq.com<\/u><\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-602","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nNew Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.leapfrog.bio\/fr\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.leapfrog.bio\/fr\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\" \/>\n<meta property=\"og:site_name\" content=\"Leapfrog Bio\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T15:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T18:23:19+00:00\" \/>\n<meta name=\"author\" content=\"leapfrogbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"leapfrogbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\"},\"author\":{\"name\":\"leapfrogbio\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\"},\"headline\":\"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal\",\"datePublished\":\"2026-01-12T15:57:48+00:00\",\"dateModified\":\"2026-01-12T18:23:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\"},\"wordCount\":975,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\",\"url\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\",\"name\":\"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#website\"},\"datePublished\":\"2026-01-12T15:57:48+00:00\",\"dateModified\":\"2026-01-12T18:23:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.leapfrog.bio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.leapfrog.bio\/#website\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"name\":\"Leapfrog Bio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.leapfrog.bio\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\",\"name\":\"Leapfrog Bio\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"contentUrl\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"width\":510,\"height\":90,\"caption\":\"Leapfrog Bio\"},\"image\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\",\"name\":\"leapfrogbio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"caption\":\"leapfrogbio\"},\"sameAs\":[\"https:\/\/www.leapfrog.bio\"],\"url\":\"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.leapfrog.bio\/fr\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/","og_locale":"fr_CA","og_type":"article","og_title":"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio","og_url":"https:\/\/www.leapfrog.bio\/fr\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/","og_site_name":"Leapfrog Bio","article_published_time":"2026-01-12T15:57:48+00:00","article_modified_time":"2026-01-12T18:23:19+00:00","author":"leapfrogbio","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"leapfrogbio","Estimation du temps de lecture":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#article","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/"},"author":{"name":"leapfrogbio","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3"},"headline":"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal","datePublished":"2026-01-12T15:57:48+00:00","dateModified":"2026-01-12T18:23:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/"},"wordCount":975,"commentCount":0,"publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/","url":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/","name":"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal - Leapfrog Bio","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/#website"},"datePublished":"2026-01-12T15:57:48+00:00","dateModified":"2026-01-12T18:23:19+00:00","breadcrumb":{"@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.leapfrog.bio\/new-data-underscoring-ability-of-leapfrog-bios-oncoslx-platform-to-identify-drug-retargeting-opportunities-for-treating-cancer-published-in-nature-portfolio-journal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.leapfrog.bio\/"},{"@type":"ListItem","position":2,"name":"New Data Underscoring Ability of Leapfrog Bio\u2019s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal"}]},{"@type":"WebSite","@id":"https:\/\/www.leapfrog.bio\/#website","url":"https:\/\/www.leapfrog.bio\/","name":"Leapfrog Bio","description":"","publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.leapfrog.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.leapfrog.bio\/#organization","name":"Leapfrog Bio","url":"https:\/\/www.leapfrog.bio\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/","url":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","contentUrl":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","width":510,"height":90,"caption":"Leapfrog Bio"},"image":{"@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3","name":"leapfrogbio","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","caption":"leapfrogbio"},"sameAs":["https:\/\/www.leapfrog.bio"],"url":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"leapfrogbio","author_link":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"},"_links":{"self":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/comments?post=602"}],"version-history":[{"count":8,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/602\/revisions"}],"predecessor-version":[{"id":610,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/602\/revisions\/610"}],"wp:attachment":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/media?parent=602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/categories?post=602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/tags?post=602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}